Clinical Trial Matching & Access
Oncology (Broad)
Key Facts
About SpeciCare
SpeciCare is a private, early-stage company revolutionizing cancer care through its proprietary Live Tissue Science™ platform, which involves the collection, cryopreservation, and banking of live tumor tissue. This service model allows patients to retain ownership of their tissue, facilitating access to personalized medicine approaches like ex vivo drug testing, organoid creation, and clinical vaccine development outside of standard clinical pathways. Founded by surgical oncologist Dr. Ken Dixon, the company targets a significant gap in oncology by ensuring preserved tissue is available for future, evolving diagnostics and therapies, positioning itself as a patient-centric service in the precision medicine landscape. Its business appears to be service-based and likely pre-revenue or early revenue, focusing on building a biobank and partnering with researchers and clinicians.
View full company profileTherapeutic Areas
Other Oncology (Broad) Drugs
| Drug | Company | Phase |
|---|---|---|
| Functional Precision Oncology Platform Validation | Known Medicine | Pre-clinical |
| Clinical Trial Program | VitroScan | N/A (Diagnostic Validation) |
| Personalized Treatment Screening | Okomera | Pre-clinical |
| Preclinical Drug Discovery Services | Okomera | Pre-clinical |
| RWE Data Pipeline | Perthera | Commercial |
| Clinical Trial Matching Service | Perthera | Commercial |
| Enhanced Liquid Biopsy Platform | Wobble Genomics | Platform Validation |
| Live Tissue Biobanking Service | SpeciCare | Service |
| Ex Vivo Therapy Testing | SpeciCare | Research |
| Personalized Vaccine Support | SpeciCare | Research |
| Organoid Creation & Biobanking | SpeciCare | Research |